Dermatology Phase 3 Deal Benchmarks — Ex-US

Understanding Dermatology Deal Benchmarks at Phase 3

Phase 3 Dermatology licensing deals in Ex-US territory command a median upfront payment of $563M, with values ranging from $364M at the low end to $807M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the dermatology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.5B to $2.5B, with a median of $2.0B. Royalty rates for dermatology assets at this stage typically fall between 7.6% and 14.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.